| Entries |
| Document | Title | Date |
|---|
| 20080226692 | Cultured Cell Sheet, Production Method Thereof, and Application Method Thereof - The problem to be solved by the present invention is to provide a cultured cell sheet that expresses phenotypes of the chondroid tissue. The problems can be solved by producing the cultured cell sheet in which cells are cultured on a surface of a cell culture support that is coated with a temperature responsive polymer having an upper or lower critical solution temperature ranging from 0° C. to 80° C. in water, including steps of: adjusting the temperature of the culture medium to a temperature below the lower critical solution temperature or above the upper critical solution temperature; bringing the cultured cell sheet in close contact with the carrier; and detaching the cultured cell sheet together with the carrier. | 09-18-2008 |
| 20080254094 | Biomaterials Carrying Cyclodextrines Having Improved Absorption Properties and Used for the Progressive and Delayed Release of Therapeutic Molecules - The present invention relates to a method of preparation of a biomaterial containing at least one bioactive molecule from a base biomaterial, characterized by the following successive operations carried out on the aforesaid base biomaterial:
| 10-16-2008 |
| 20080286332 | Implantable medical devices with a topcoat layer of phosphoryl choline acrylate polymer for reduced thrombosis, and improved mechanical properties - The present invention relates to implantable medical devices coated with phosphoryl choline acrylate polymer topcoat layer, an acrylate copolymer layer containing a therapeutic agent, and their use in the treatment of vascular diseases. | 11-20-2008 |
| 20080299173 | CHONDROCYTE CONTAINER AND METHOD OF USE - Devices and methods for delivering a therapeutic agent produced via a genetically-altered chondrocyte are provided. More specifically, the device includes a housing which defines a cell chamber configured to retain a large volume of chondrocytes while selectively releasing therapeutic agents produced via these entrapped cells. In an exemplary embodiment, the cell chamber can be configured such that a portion of cells can be positioned at least about 1.5 mm from an external wall of the device (i.e., about 1.5 mm away from an external nutrient supply). For example, the cell chamber can have a tubular configuration having a length and a diameter wherein each of these dimensions is at least about 3 mm (thereby the central core to the chamber is at least about 1.5 mm from the outer wall of the device). | 12-04-2008 |
| 20090010991 | Nasal Passage Stent - A drug coated nasal stent implant that provides filtration of environmental pollutants and airborne allergens from inhaled air regulating the air before it is ingested into the remainder of the respiratory tract. The coatings include but are not limited to a variety of allergenic-specific antigen targeted antibodies as well as anti-inflammatory drugs such as antihistamines | 01-08-2009 |
| 20090035350 | Polymers for implantable devices exhibiting shape-memory effects - The present invention is directed to polymeric compositions comprising a biodegradable copolymer that possesses shape-memory properties and implantable devices (e.g., drug-delivery stents) formed of materials (e.g., a coating) containing such compositions. The polymeric compositions can also contain at least one non-fouling moiety, at least additional biocompatible polymer, at least one biobeneficial material, at least one bioactive agent, or a combination thereof. The polymeric compositions are formulated to possess good mechanical, physical and biological properties. Moreover, implantable devices formed of materials comprising such compositions can be delivered to the treatment site in a conveniently compressed size and then can expand to dimensions appropriate for their medical functions. | 02-05-2009 |
| 20090047325 | XENOTRANSPLANT FOR CNS THERAPY - Disclosed are compositions and methods for the xenotransplantation treatment of neurological diseases of the central nervous system of a mammal. | 02-19-2009 |
| 20090098186 | METHOD AND SYSTEM FOR COATING A SURFACE OF A MEDICAL DEVICE WITH A THERAPEUTIC AGENT AND DRUG ELUTING MEDICAL DEVICES MADE THEREBY - A multi-layer drug coated medical device such as for example an expandable vascular drug eluting stent is formed by vacuum pulse spray techniques wherein each layer is irradiated to improve adhesion and/or drug elution properties prior to formation of subsequent layers. Layers may be homogeneous or of diverse drugs. Layers may incorporate a non-polymer elution-retarding material. Layers may alternate with one or more layers of non-polymer elution-retarding materials. Polymer binders and/or matrices are not used in the formation of the coatings, yet the pure drug coatings have good mechanical and elution rate properties. Systems, methods and medical device articles are disclosed. | 04-16-2009 |
| 20090104247 | Coating Designs For The Tailored Release Of Dual Drugs From Polymeric Coatings - Provided herein are coating designs for the tailored release of two therapeutic agents from polymer coatings and methods of making and using the same. | 04-23-2009 |
| 20090117170 | SEGMENTED DEVICE FOR THE DELAYED RELEASE OF MOLECULES IN A TANGENTIAL DIRECTION THROUGH THIN FILMS AND USES THEREOF - The present invention of a segmented release device (sandwich construction with reservoir) for molecules (active compounds, medicaments, diagnostic, therapeutic and chemical reagents) is based on a construction which makes possible a constant release rate through diffusion-permeable intersegment films partially or completely filled with liquid of the neighboring media. The molecules pass here from the reservoir of the device into the outer medium by diffusion exclusively through the intersegment films. These intersegment films are adjustable in their thickness and composition in the manner specified in each case. | 05-07-2009 |
| 20090202608 | Devices, formulations, and methods for delivery of multiple beneficial agents - The present invention relates to osmotic delivery devices, formulations, and methods for delivery of two or more beneficial agents. In one aspect, the present invention provides osmotic delivery devices useful for substantially concurrent administration of two or more beneficial agents. In another aspect, the present invention provides beneficial agent formulations for use in the osmotic delivery devices. The formulations include formulations wherein beneficial agents are soluble in the vehicle, suspension formulations comprising particle formulations of one or more beneficial agent, and combinations thereof. Further, methods for treatment of a variety of diseases or conditions using two or more beneficial agents are disclosed, wherein the methods are preferably practiced using the osmotic delivery devices and/or formulations of the invention. | 08-13-2009 |
| 20090238855 | LAMINATE SHEET ARTICLES FOR TISSUE REGENERATION - The invention is to articles of extracellular matrix. The articles comprise one or more sheets of mammalian extracellular matrix laminated together. A single sheet can be folded over and laminated on 3 sides. Two or more sheets can be laminated to each other at their edges. The sheets can further encase a composition comprising a cell or cells, such as for example, a stem cell. A single sheet can be folded over to encase a composition, or rolled to encase a composition with lamination at either end of the roll, for example. The invention also includes methods of using these articles to regenerate tissue at tissue defects, or heal wounds in damaged tissue. | 09-24-2009 |
| 20090238856 | POLYSULFONE BLOCK COPOLYMERS AS DRUG-ELUTING COATING MATERIAL - A polymeric composition comprising a polysulfone polymer and an elastomeric polymer for use as a coating composition for coating an implantable device, such as a DES, and methods of making and using the implantable device are provided. | 09-24-2009 |
| 20090263453 | Methods and Compositions for Treating Pain Comprising a Statin - Methods and compositions are provided for reducing, treating or preventing pain and/or inflammation in a patient in need of such treatment, the methods and compositions comprising administering a therapeutically effective amount of a statin or pharmaceutically acceptable salt thereof to a target tissue site beneath the skin. | 10-22-2009 |
| 20090263454 | ALPHA AND BETA ADRENERGIC RECEPTOR AGONISTS FOR TREATMENT OF PAIN AND / OR INFLAMMATION - Effective treatments of pain and/or inflammation are provided. Through the administration of an effective amount of at least one alpha adrenergic agonist and at least one beta adrenergic agonist at or near a target site, one can reduce, prevent or treat pain and/or inflammation. | 10-22-2009 |
| 20100034866 | Fused stem cells useful for the treatment of diabetes and methods thereof - Methods disclosed include methods of treating T1DM, said method comprising delivering a therapeutic amount of β-MSC to a subject in need thereof. Further disclosed are fusion cells comprising and MSC and a second cell wherein the nuclei of the MSC and the second cell are not fused in the fusion cell. | 02-11-2010 |
| 20100074941 | Absorbable, permeability-modulated barrier composites and applications thereof - Absorbable barrier composites are designed for modulated gas and water permeability depending on clinical use and are formed of at least two physicochemically distinct components, one of which is a film adjoined to a knitted mesh and/or electrostatically spun, non-woven fabric. Depending on the physicochemical properties of the barrier composite, it can be used in neurological and urinogenital surgical procedures as well as tissue engineering and/or as physical barriers to prevent adhesion formation following several types of surgical procedures. | 03-25-2010 |
| 20100098742 | FABRICATION OF TISSUE LAMINA USING MICROFABRICATED TWO-DIMENSIONAL MOLDS - Methods and materials for making complex, living, vascularized tissues for organ and tissue replacement, especially complex and/or thick structures, such as liver tissue is provided. Tissue lamina is made in a system comprising an apparatus having (a) a first mold or polymer scaffold, a semi-permeable membrane, and a second mold or polymer scaffold, wherein the semi-permeable membrane is disposed between the first and second molds or polymer scaffolds, wherein the first and second molds or polymer scaffolds have means defining microchannels positioned toward the semi-permeable membrane, wherein the first and second molds or polymer scaffolds are fastened together; and (b) animal cells. Methods for producing complex, three-dimensional tissues or organs from tissue lamina are also provided. | 04-22-2010 |
| 20100098743 | MEDICAL SUBSTITUTE MEMBRANE, USE THEREOF, AND METHOD FOR REPAIR OF MEMBRANE TISSUE IN LIVING BODY - An object is to overcome the disadvantages of a conventional lyophilized amniotic membrane or the like which causes damages in a cell membrane or an amniotic membrane tissue and is therefore not suitable for use as a substitute membrane for a membrane tissue in a living body, and to provide a novel medical substitute membrane composed of a dried amniotic membrane, which can be used as a substitute membrane for a membrane tissue in a living body. The dried amniotic membrane is produced by drying a fresh amniotic membrane, which envelopes an embryo of an animal including human, and can be used as a substitute membrane for a membrane tissue in a living body; the dried amniotic membrane is dehydrated and dried so that the dried amniotic membrane can be stored in a dry air in a sterile state; when hydrated again by immersing in water or a buffer solution, the amniotic membrane still has an epithelial cell, a basement membrane and a connective tissue which constitute the fresh amniotic membrane. The dried amniotic membrane is useful as a medical substitute membrane for a membrane tissue in a living body such as a dura mater, a meninx, a pericardium, a pleura and a peritoneum. | 04-22-2010 |
| 20100124564 | ENCAPSULATION OF PANCREATIC CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS - The present invention relates to methods for encapsulating pancreatic progenitors in a biocompatible semi-permeable encapsulating device. The present invention also relates to production of human insulin in a mammal in response to glucose stimulation. | 05-20-2010 |
| 20100150984 | BIO-ARTIFICIAL PANCREAS AND A PROCEDURE FOR PREPARATION OF SAME - The present invention generally relates to implantable devices for producing insulin in diabetic animals and to methods of making same. Some embodiments include amphiphilic biomembranes for use in biological applications (e.g., as an alternative and/or supplemental insulin source). Some embodiments also include live insulin-producing cells contained within one or more amphiphilic membranes so as to prevent or diminish an immuno-response and/or rejection by the host. | 06-17-2010 |
| 20100196439 | Angiogenesis Mechanism and Method, and Implantable Device - Various methods and devices are provided for providing therapy to a living body. In one embodiment, an implanted permeable container has living cells provided therein, and various nutrients and/or agents are provided into the container to promote cell life. | 08-05-2010 |
| 20100203101 | BIO-MEMBRANE FOR TISSUE REGENERATION - A bio-membrane with angiogenic activity for implant in tissue regeneration and repair, including bone reconstruction and the repair of skin and soft tissue lesions is described, essentially constituted by a gel able to provide support and growth and/or differentiation and/or angiogenic factors for the full in vivo functionality of the cell, containing also mesenchymal stem/precursor cells, an implant device for reconstructive surgery of bone tissue, of skin and soft tissue lesions which comprises the bio-membrane, and a method for its obtainment. Use of the gel alone for tissue regeneration and of adhesive plasters that comprise it is also described. | 08-12-2010 |
| 20100255059 | Artificial micro-gland - A micro-scale artificial gland is disclosed in the form of an independent unit for promoting biological activity. The artificial gland includes cells formed in a membrane enclosing a reservoir. The reservoir is a bio-reactor capable of containing a product of activity of the cells. The reservoir comprises a gas, a liquid, and a gel and preferably also contains nanoparticles, a buffer, a surfactant, and, a gel precursor. The reservoir may also contain cells. Nanoparticles may also surround the artificial gland to form a protective coating. A variety of methods are disclosed for making the artificial gland by directed assembly of cells into the artificial micro-gland by gel, liquid or bubble templating. All involve coating the surface of gel, droplet or bubble with the living cells and the stabilizing the cells on the surface of gels, droplets or bubbles. | 10-07-2010 |
| 20100260816 | INDUCTION OF IMMUNOLOGICAL TOLERANCE - A method of creating tolerance to transplanted cells, tissue, or organs without the need for continuous immunosuppression. A tolerizing dose of a cell or tissue within a membrane structure is implanted into a patient. Once the patient becomes tolerant to the cell or tissue, a tissue or organ is implanted which will no longer be recognized as foreign matter. The method makes animal organs practical for human use, prevents autoimmune destruction as well as immune rejection. It has applications in treatment and prevention of many mammalian diseases. | 10-14-2010 |
| 20100285090 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR - Methods and compositions for the biological repair of cartilage using a hybrid construct combining both an inert structure and living core are described. The inert structure is intended to act not only as a delivery system to feed and grow a living core component, but also as an inducer of cell differentiation. The inert structure comprises concentric internal and external and inflatable/expandable balloon-like bio-polymers. The living core comprises the cell-matrix construct comprised of HDFs, for example, seeded in a scaffold. The method comprises surgically removing a damaged cartilage from a patient and inserting the hybrid construct into the cavity generated after the foregoing surgical intervention. The balloons of the inert structure are successively inflated within the target area, such as a joint, for example. Also disclosed herein are methods for growing and differentiating human fibroblasts into chondrocyte-like cells via mechanical strain. | 11-11-2010 |
| 20100303887 | DHA and PEDF, a Therapeutic Composition for Nerve and Retinal Pigment Epithelial Cells - The combination of pigment epithelium-derived factor (PEDF) and docosahexaenoic acid (DHA) has been discovered to act synergistically to enhance cell survival and decrease apoptosis in retinal pigment epithelial (RPE) cells. PEDF and DHA synergistically protected RPE cells by confronted with oxidative stress by blocking apoptotic cell death and increasing the synthesis of the important mediator neuroprotectin D 1. Administering a composition comprising PEDF and DHA will halt or slow down the initiation and progression of macular degeneration, retinitis pigmentosa and retinal degeneration. In addition, the topical application of the combination of PEDF and DHA was found to promote cornea nerve regeneration after refractive surgery, and thus this combination could be used to prevent the complications of refractive surgery and certain diseases, e.g., neurotrophic keratitis due to Herpes virus. | 12-02-2010 |
| 20100310627 | Xenotransplant for Stroke Therapy - Disclosed are implant compositions and methods for treatment of neurological diseases of the central nervous system of a mammal. | 12-09-2010 |
| 20100316690 | Modular assembly of tissue engineered constructs - Scaleable, vascularised tissue constructs that are composed of a multiplicity of cell containing, discrete and separable modules, methods of fabricating same and uses thereof. The tissue construct is a tissue substitute used in tissue transplantation or substitution or for the purpose of in vitro mimic of normal tissue. | 12-16-2010 |
| 20100330146 | CONTACT LENSES FOR EXTENDED RELEASE OF BIOACTIVE AGENTS CONTAINING DIFFUSION ATTENUATORS - An appliance for the delivery of at least one bioactive agent to the eye has at least one diffusion attenuator within a hydrophilic or silicone-hydrogel contact lens. The bioactive agent can be a drug or a nutraceutical. The diffusion attenuator can be a plurality of solid particles or phase separated liquid aggregates within at least one continuous phase of the lens where the diffusion attenuators promote a tortuous path for the diffusion of the bioactive agent to mediate the rate by which the bioactive agent diffuses from the contact lens. The diffusion attenuator can be homogeneously dispersed throughout at least one continuous phase of the lens to modify the diffusivity of the bioactive agent through that phase. The diffusion attenuator can have little or no affinity for the bioactive agent or can be miscible with the bioactive agent. The diffusion attenuator can be incorporated while forming the contact lens by polymerization of a monomer mixture containing the diffusion attenuator. For liquid diffusion attenuators, the liquid can be co-absorbed with a solvent into the lens followed by removal of the solvent, where the bioactive agent can be co-absorbed or subsequently absorbed after the loading of the diffusion attenuator. The diffusion attenuator can be Vitamin E. | 12-30-2010 |
| 20110045055 | MEDICAL DEVICES CONTAINING THERAPEUTIC AGENTS - According to one aspect of the invention, implantable or insertable medical devices are provided which can delay release of one or more therapeutic agents for a predetermined time after implantation in a subject. In various embodiments, a therapeutic agent delivery profile of this type is provided by employing a temporary barrier layer which initially permits little to no release of the therapeutic agent, but which layer permits much greater release levels after a predetermined period of time. Other aspects of the invention relate to methods of forming such devices and to methods of using such devices. | 02-24-2011 |
| 20110086083 | IMPLANT DEVICES FOR MODULATING BIOACTIVE AGENT RELEASE PROFILES - Described herein are implant devices comprising at least one exposed biodegradable inner core surface, the inner core being surrounding partially by a membrane sheath which comprises a biocompatible polymer. A bioactive agent can be released from the inner core. | 04-14-2011 |
| 20110104233 | FLOWABLE COMPOSITION THAT SETS TO A SUBSTANTIALLY NON-FLOWABLE STATE - Flowable compositions and methods are provided for delivering a therapeutic agent at or near a target tissue site beneath the skin of a patient, the flowable composition comprising (i) a solvent, (ii) a polymer and (iii) an effective amount of the therapeutic agent, the flowable composition being capable of setting to form a substantially non-flowable composition at a physiological temperature or as the solvent contacts bodily fluid at or near the target tissue site, wherein the substantially non-flowable composition is capable of releasing the therapeutic agent over a period of at least one day and the target tissue site comprises at least one muscle, ligament, tendon, cartilage, spinal disc, spinal foraminal space near the spinal nerve root, facet or synovial joint, or spinal canal. | 05-05-2011 |
| 20110223233 | MICROFABRICATED NANOPORE DEVICE FOR SUSTAINED RELEASE OF THERAPEUTIC AGENT - A drug delivery device that includes a capsule for implantation into the body; the capsule further includes a reservoir for containing a substance such as a therapeutic agent, at least one port for allowing the substance to diffuse from or otherwise exit the reservoir, and a nanopore membrane in communication with the capsule at or near the exit port for controlling the rate of diffusion of the substance from the exit port. The device also includes an optional screen for providing structural stability to the nanopore membrane and for keeping the pores of the nanopore membrane clear. One embodiment of the drug delivery device includes an osmotic engine internal to the device for creating fluid flow through the device. | 09-15-2011 |
| 20110236457 | Micronized Device for the Delivery of Biologically Active Molecules and Methods of Use Thereof - The invention provides micronized encapsulated cell therapy devices that are capable of delivering a biologically active molecule to the eye. Also provided are methods of using the same to deliver biologically active molecules to the eye and to treat ophthalmic disorders in patients suffering there from. | 09-29-2011 |
| 20120021039 | EXPRESSION OF NEUROPEPTIDES IN MAMMALIAN CELLS - The present application relates to expression constructs capable of securing correct processing of neuropeptides upon expression in mammalian cells, and to mammalian cells secreting correctly processed peptides. One exemplary peptide is galanin. The application also relates to devices containing neuropeptide secreting cells, which devices may be used for the treatment of epilepsy and other disorders of the nervous system. All references cited herein are incorporated by reference. | 01-26-2012 |
| 20120258162 | CONTROLLED DELIVERY OF MOLECULES FROM A BIOINTERFACE - Disclosed are methods and apparatuses for delivery of bioactive molecules. The drug delivery systems include an implantable medical device which significantly reduces or suppresses adverse biological responses associated with implantable devices and also promotes vascularization in tissues surrounding the implanted device. The disclosure also relates to drug delivery systems designed to vary the rate of delivery of bioactive molecules with a change in the physiological environment. | 10-11-2012 |
| 20130039966 | Bone Semi-Permeable Device - Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects. | 02-14-2013 |
| 20130108680 | IMPLANTABLE TIZANIDINE COMPOSITIONS AND METHODS OF TREATMENT THEREOF | 05-02-2013 |
| 20140079754 | MICROFABRICATED NANOPORE DEVICE FOR SUSTAINED RELEASE OF THERAPEUTIC AGENT - A drug delivery device that includes a capsule for implantation into the body; the capsule further includes a reservoir for containing a substance such as a therapeutic agent, at least one port for allowing the substance to diffuse from or otherwise exit the reservoir, and a nanopore membrane in communication with the capsule at or near the exit port for controlling the rate of diffusion of the substance from the exit port. The device also includes an optional screen for providing structural stability to the nanopore membrane and for keeping the pores of the nanopore membrane clear. One embodiment of the drug delivery device includes an osmotic engine internal to the device for creating fluid flow through the device. | 03-20-2014 |
| 20140127280 | INTRAUTERINE DELIVERY SYSTEM FOR CONTRACEPTION - The invention relates to a method for contraception and for reducing menstrual problems and inducing amenorrhea, wherein an intrauterine delivery device is used for the controlled release of a combination of progestogen or a drug having a progestogenic activity and at least one therapeutically active substance capable of preventing or suppressing abnormal and/or irregular endometrial bleeding over a prolonged period of time. | 05-08-2014 |
| 20140248328 | Methods of treating amniotic membranes using supercritical fluids and compositions and apparatuses prepared therefrom - A method of sterilizing compositions prepared from amniotic membrane tissues may include harvesting placental tissue, separation of amniotic membrane tissue, and treatment of the amniotic membrane tissue with a supercritical fluid such as carbon dioxide. Treatment with supercritical fluid may subject the amniotic membrane tissue to conditions sufficient to sterilize the tissue yet maintain at least some biological function of the sterilized composition. Compositions described herein may be used as tissue grafts, wound dressings, cell culture substrates, or other substrates for use in tissue engineering. | 09-04-2014 |
| 20140255462 | Xenotransplant Compositions and Methods of Stroke Therapy - Disclosed are implant compositions and methods for treatment of neurological diseases of the central nervous system of a mammal. | 09-11-2014 |
| 20150024024 | Cell Lines That Produce Prostaglandin F2 Alpha (PGF2A) And Uses Thereof - Cells and cell lines that are genetically modified to express the hCox-2 enzyme, which results in the upregulation of prostaglandin F2 alpha (PGF2a) on the cells have been obtained. Encapsulated cell therapy devices containing such cells or cell lines that are capable of delivering PGF2a, as well as methods of using these devices to deliver PGF2a to the eye and to treat ophthalmic disorders in patients suffering therefrom are also described. | 01-22-2015 |
| 20150030657 | SMOOTH MUSCLE CELL CONSTRUCTS - The present invention relates to the regeneration, reconstruction, augmentation or replacement of luminal organs or tissue structures in a subject in need using scaffolds seeded with autologous or non-autologous cell populations that are or are not derived from the corresponding organ or tissue structure that is the subject of the regeneration, reconstruction, augmentation or replacement. | 01-29-2015 |
| 20150343114 | BONE DELIVERY SYSTEM HAVING A THERAPEUTIC AGENT - A covering for delivering a therapeutic agent to a surgical site is provided. The covering may include a single or multi-compartment structure configured to at least partially retain the therapeutic agent until the covering is placed at a surgical site. Upon placement, the covering may facilitate transfer of the therapeutic agent to the surgical site. In some embodiments, the covering comprises an antimicrobial agent, a hemostatic agent, an anti-inflammatory agent, and/or a growth factor. | 12-03-2015 |
| 20150374637 | SEMI-PERMEABLE CAPSULAR MEMBRANE WITH TAPERED CONDUITS FOR DIABETES FUNCTIONAL CURE - Some embodiments of the present disclosure include an encapsulated islet for treating diabetes. The encapsulated islet may include a semi-permeable capsular membrane having a plurality of layers including an outer immunoprotection layer, a bridging layer, and an inner backbone layer, each layer having a plurality of pores, wherein the pores increase in size from the immunoprotection layer to the backbone layer, creating the tapered conduits. The semi-permeable capsular membrane may include the following layers, in order from outermost layer to innermost layer: an immunoprotection layer, a bridging layer, and a backbone layer. With proper balancing of membrane thickness and tapered pore size distribution, the encapsulated islets may offer a diabetes treatment or functional cure without immunosuppressive drugs. | 12-31-2015 |
| 20160038640 | ENCAPSULATION OF PANCREATIC CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS - The present invention relates to methods for encapsulating pancreatic progenitors in a biocompatible semi-permeable encapsulating device. The present invention also relates to production of human insulin in a mammal in response to glucose stimulation. | 02-11-2016 |
| 20160058911 | MULTI-STEP METHOD FOR FABRICATING TISSUE ENGINEERING BONE - A multi-step method for fabricating a tissue engineering bone comprises the following steps: (1) scaffold repair and pre-vascularization: fabricating a tissue engineering bone scaffold at a bone defect site, and conducting pre-vascularization; and (2) post-implantation of a seed cell for bone tissue engineering: after an inflammatory reaction period, combined with time for micro-vessel in-growth, implanting an osteogenic-induced seed cell into a tissue engineering bone scaffold at the bone defect site. In certain embodiments, the step (2) of post-implantation of a seed cell for bone tissue engineering is performed 7 to 14 days after the step (1) of scaffold repair and pre-vascularization. The method can be used to rapidly fabricate a large section of tissue engineering bone, greatly reduce usage of the seed cell for bone tissue engineering required in repair of per unit volume of bone tissue, and improve the utilization rate of the seed cell. | 03-03-2016 |
| 20160067390 | METHODS FOR IN VIVO AND IN VITRO USE OF GRAPHENE AND OTHER TWO-DIMENSIONAL MATERIALS - Two-dimensional materials, particularly graphene-based materials, having a plurality of apertures thereon can be formed into enclosures for various substances and introduced to an environment, particularly a biological environment (in vivo or in vitro). One or more selected substances can be released into the environment, one or more selected substances from the environment can enter the enclosure, one or more selected substances from the environment can be prevented from entering the enclosure, one or more selected substances can be retained within the enclosure, or combinations thereof. The enclosure can for example allow a sense-response paradigm to be realized. The enclosure can for example provide immunoisolation for materials, such as living cells, retained therein. | 03-10-2016 |
| 20160199311 | SEMI-PERMEABLE ENCAPSULATION SYSTEM WITH TAPERED CONDUITS FOR DIABETES REVERSAL | 07-14-2016 |
